New drug hope for rare autoimmune disease fizzles in early trial
NCT ID NCT04918147
First seen Feb 05, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tested the drug elotuzumab for people with active IgG4-related disease (IgG4-RD), a rare condition where the body attacks its own tissues. The trial aimed to see if adding elotuzumab to standard steroid treatment was safe and effective. Only 8 people enrolled before the study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Healthcare
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic: Pulmonary and Critical Care Medicine
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.